A male contraceptive targeting germ cell adhesion

Area of Science:

• Reproductive Biology
• Pharmacology
• Cell Biology

Background:

• Spermatogenesis relies on germ cell adhesion to Sertoli cells via specific junctions.
• Compromised adhesion leads to germ cell detachment and infertility.
• Adjudin has shown potential for inducing germ cell loss but with systemic side effects.

Purpose of the Study:

• To develop a targeted delivery system for Adjudin to the testis.
• To enhance Adjudin's efficacy as a male contraceptive.
• To mitigate Adjudin's adverse systemic effects.

Main Methods:

• Conjugating Adjudin to a recombinant follicle-stimulating hormone (FSH) mutant carrier.
• Administering the Adjudin-FSH conjugate intraperitoneally in adult rats.
• Evaluating the induction of infertility and assessing systemic toxicity.

Main Results:

• The Adjudin-FSH conjugate induced infertility at a significantly lower dose (0.5 microg/kg b.w.) compared to oral Adjudin (50 mg/kg b.w.).
• Targeted delivery substantially increased Adjudin's selectivity and efficacy.
• This approach minimized adverse effects observed with systemic Adjudin administration.

Conclusions:

• Targeted delivery of Adjudin via an FSH carrier is a promising strategy for male contraception.
• This method enhances therapeutic index by increasing efficacy and reducing toxicity.
• Further research into Adjudin-FSH conjugates could lead to novel male contraceptive options.